Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive two-year results from the Phase 3 PANORAMA trial evaluating EYLEA ® (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately ...

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...

Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...

Age-related macular degeneration (AMD) is the most common cause of central vision loss and blindness in adults. Wet AMD comprises 25% of all cases of AMD and is characterized by new blood vessel ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO 2025 ...

What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...